In 1997, Bayer and Barr settled. As part of the settlement, Barr agreed to postpone marketing the generic version of Cipro until the patent expired and to a consent judgment affirming the patent's validity. In return, Bayer agreed to pay significant sums to Barr and to supply Cipro for licensed resale six months before the patent expired. From 1997 to 2003, Bayer paid Barr $398.1 million. Bayer's profits from Cipro exceed $1 billion.